Document is current

Article History

Received: 17 September 2024

Accepted: 18 November 2024

First Online: 2 January 2025

Conflict of interest

: P. Werminghaus reports participation in advisory boards and/or personal fees for lectures from AstraZeneca, Bencard Allergie GmbH, GSK, Sanofi, Novartis and Stallergenes. S. Becker reports about grants and/or personal fees as advisor and for lectures from Bencard Allergie, Brain, Karl Storz, Altamira, Allergy Therapeutics, HAL Allergy, Allergopharma, ALK Abelló, Sanofi, Novartis, GSK, Astra Zeneca, MSD, Viatris, Ambu, Stryker and Federal Ministry of Education and Research. L. Klimek reports about grants and/or personal fees from Allergopharma, Viatris, HAL Allergy, ALK Abelló, Leti Pharma, Stallergenes, Quintiles, Sanofi, ASIT biotech, Lofarma, Allergy Therapeutics, Astra Zeneca, GSK, Inmunotek, Cassella med, Novartis, Regeneron Pharmaceuticals, Roxall Medizin, outside of the submitted work. Membership at AeDA, DGHNO, Deutsche Akademie für Allergologie and klinische Immunologie, HNO-BV, GPA and EAACI. L. Klimek is the editor in chief of Allergo Journal and Allergo Journal International. M. Cuevas reports about personal fees for lectures from von ALK-Abelló, Allergopharma, Astra Zeneca, Bencard Allergie/Allergy Therapeutics, GSK, HAL Allergy, Leti Pharma, Novartis, Roxall, Sanofi-Aventis, and Stallergenes, outside the submitted work. Other nonfinancial interests: Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC). M. Rosewich reports about participation in advisory boards and/or personal fees for lectures from Bencard, GSK, Sanofi, HAL and Leti. He is member of GPA, GPP, EAACI and ERS. F. Hermanns, A. Graessel, P.-J. de Kam and M. F. Kramer are employees of Bencard Allergie GmbH/Allergy Therapeutics.